iBio
Update in progressIBIO (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
iBio, Inc. is a preclinical biotechnology company developing AI-driven antibody solutions for cardiometabolic disease and obesity. Its platforms include EngageTx (CD3 T-cell engager panel), ShieldTx (conditioned-activated antibodies), StableHu (AI antibody optimization), and AI epitope steering. Pipelines include IBIO-101, CCR8, and MUC16 antibodies; EGFRvIII and TROP-2 x CD3 bispecifics. Collaboration with AstralBio. Based in San Diego, formed 2008, renamed 2009.
Company score
- Sentiment
- 0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.39
- Governance
- 0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Martin B. Brenner D.V.M., Ph.D.
- Founded2008
- Employees20
- Websiteibioinc.com
Identifiers
- ISINUS4510332038
- FIGIBBG000D5F2L9
- CUSIP451033104
- CIK0001420720